Minimally invasive arthroplasty in the management of hip arthritic disease: systematic review and economic evaluation

Coyle D, Coyle K, Vale L, de Verteuil R, Imamura M, Glazener C, Zhu S
Record ID 32006001175
English
Authors' recommendations: Despite the number of studies identified, there was little evidence of any longer-term differences between MI THR and standard THR. This is mainly because of the lack of data available. In addition, surrogates for longer-term outcomes provided insufficient information with which to make judgements about longer-term performance. Overall, it seems likely that the MI approach offers some peri-operative advantages regarding blood loss and operative time, although these may be of limited clinical significance. The MI approach may also offer a shorter recovery period, as identified by the shorter length of hospital stay and time to return to usual activities. Two economic evaluations of MI THR were identified. Both were of poor quality and did not provide useful information.The economic analysis found little difference between therapies in costs and QALYs. Single-incision MI THR was more expensive with more QALYs. The incremental cost per QALY gained was$148,000. The results were sensitive to changes in parameters, and value of information analysis confirms the benefit from conducting more research. In conclusion, given the level of clinical evidence available and the results of the economic evaluation, greater value seems to be gained from conducting a larger definitive RCT focusing onlong-term revision rates rather than providing funding for the expansion of MI THR.
Details
Project Status: Completed
URL for project: http://www.cadth.ca/media/pdf/336_Invasive-Arthroplasty-Man-Hip-Arthritic-Disease_tr_e.pdf
Year Published: 2008
URL for published report: http://www.cadth.ca/index.php/en/hta/reports-publications/search/publication/794
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Arthroplasty, Replacement, Hip
  • Osteoarthritis, Hip
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.